All News

Though antibiotics are crucial, concern about overuse in hospitals and inappropriate prescribing practices fuels debate about the complex relationship between antibiotic use and antimicrobial resistance.

“Err on the side of caution. One large data breach could [affect all] your patients, your employees, and yourself.”

Armand Balboni, MD, PhD, chief executive officer of Appili Therapeutics, discusses the potential for favipiravir, an antiviral medication, for treating COVID-19 in certain populations.

The right products can help manage symptoms of autoimmune diseases.

“As pharmacists, we must continue to recommend vaccinations to all our patients.”

Pharmacists must be tuned in to the latest technology for patients who monitor blood glucose.

Virtual care takes center stage amid the pandemic.

Officials with the FDA have approved imipenem, cilastatin, and relebactam (Recarbrio, Merck) for the treatment of adults with hospital-acquired and ventilator-associated bacterial pneumonia. 

Patients seeking vitamin or herbal supplements for health and wellness often believe that these are safer than conventional OTC and prescription pharmaceutical products; however, so-called natural remedies come with their own set of health risks.

“Are employers really stepping up to take care of their health providers? I think [that] is something that also probably needs to change.”

Here's a roundup of the latest coronavirus-related news.

Julie Ann Justo, PharmD, infectious diseases clinical pharmacist and assistant professor at the University of South Carolina College of Pharmacy, discusses the treatment potential for remdesivir for SARS-CoV-2, as well as distribution strategies for the drug.

Recombinant herpes zoster (HZ) vaccine (Shingrix) induced a strong and persistent immune response in older adults, regardless of previous receipt of live-attenuated HZ vaccine.

A recent analysis showed a surge in prescription fills for hydroxychloroquine/chloroquine, likely due to off-label prescribing for coronavirus disease 2019. 

Survey results reveal improvements and challenges in the workplace.

“Testing is coming, but getting there is a step-by-step process, and you need to work out the logistics.”

Ixekizumab (Taltz, Eli Lilly) is the first interleukin-17A antagonist to be approved for non-radiographic axial spondyloarthritis.

Bristol Myers Squibb announced the commercial US launch of ozanimod (Zeposia) for the treatment of relapsing forms of multiple sclerosis.

Impax requested that pharmacists who have dispensed Impax’s epinephrine injection, USP auto-injector 0.3 mg since December 20, 2018 contact all patients who received the device and provide instructions for inspection.

The study’s authors examined the opportunity to decrease the overall cost of bortezomib by $300-400 million by switching patients to the generic version.

Pharmacies and pharmacists can help the rapid deployment of COVID-19 vaccines when available, NACDS said. 

IW-3718, an investigational adjunct therapy to proton pump inhibitors for refractory GERD, showed favorable results in reducing heartburn severity and other symptoms.

An analysis found that US patients with COVID-19 are experiencing longer hospital stays and higher rates of ICU admissions than patients in China.

Can coronavirus-related stress cause shingles?

This is the first regulatory approval for aspirin plus ticagrelor dual antiplatelet therapy for individuals with high cardiovascular risk but without prior instances of heart attack or stroke.

Officials with the FDA approved atezolizumab (Tecentriq, Genentech) in combination with bevacizumab (Avastin) for the treatment of patients with unresectable or metastatic hepatocellular carcinoma who have not received prior systemic therapy.

A systematic review of medical cannabis and cannabinoid use in oncology care demonstrated varied results. 

Targeted therapy osimertinib (Tagrisso) demonstrated significant improvements in disease-free survival in patients with localized non-small cell lung cancer (NSCLC) who were treated following surgery.

Apotex Corp is voluntarily recalling all lots of metformin hydrochloride extended-release tablets, USP 500 mg, within expiry to retail level.

The study marks the first time that the drug has demonstrated benefit for front-line therapy in patients with this type of colorectal cancer.